Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Failure 1Hepatitis C 1Hepatitis B 1Hepatic Insufficiency 1HIV Infections 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 30Capecitabine 26Fluorouracil 20Irinotecan 19tislelizumab 18apatinib 16Paclitaxel 13Cisplatin 13S 1 (combination) 12Radiotherapy 12Leucovorin 11Bevacizumab 11Laparoscopy 9Drug Therapy 9Cetuximab 9sintilimab 8Endoscopic Mucosal Resection 8Gemcitabine 7Docetaxel 7camrelizumab 6XELOX 6Surgical Procedures, Operative 6Radiation 6Propranolol 6Nivolumab 6Neoadjuvant Therapy 6Immune Checkpoint Inhibitors 6Folfox protocol 6Levoleucovorin 5HMPL-013 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Raltegravir Potassium × Gastrointestinal × Clear all
NCT01022476 2026-04-06

LIVERAL

ANRS, Emerging Infectious Diseases

Phase 1/2 Completed
14 enrolled
Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, HIV Infections, Liver Failure, Hepatic Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡